The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, talk ...
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, discuss ...
This year’s conference highlighted a number of critical areas in clinical R&D including financial management, representation, ...
In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, address ...
At the current rate of progress, it will take until 2158 to reach full gender parity based on a global measure of opportunity ...
Genomics has long been a primary focus in precision medicine, but other areas of research are increasingly being used to help ...
In this video interview, Yael Elish, founder, CEO, StuffThatWorks; and Julie Ross, president, CEO, Advanced Clinical, ...
Teams must work together with technology solutions and optimize integration to unlock their full potential. Clinical trials ...
In this video interview, Iddo Peleg, CEO and co-founder at Yonalink, talks innovation in clinical technology and how the FDA can continue to promote its adoption.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results